Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Decline in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 5,200 shares, a decline of 13.3% from the August 31st total of 6,000 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 30,200 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KPRX. Maxim Group upgraded shares of Kiora Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 13th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a research report on Thursday, August 22nd.

Kiora Pharmaceuticals Trading Down 0.6 %

Shares of NASDAQ:KPRX opened at $3.43 on Friday. The business’s fifty day moving average price is $3.78 and its two-hundred day moving average price is $4.68. Kiora Pharmaceuticals has a one year low of $3.00 and a one year high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.42. The company had revenue of $0.02 million for the quarter. As a group, sell-side analysts expect that Kiora Pharmaceuticals will post 1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for approximately 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.